In Vivo DA D1 Receptor Selectivity of NNC 112 and SCH 23390

[1]  Mark Slifstein,et al.  Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  C. Halldin,et al.  Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study , 2006, Psychopharmacology.

[3]  P. F. M. Janssen,et al.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding , 1996, Psychopharmacology.

[4]  P. Goldman-Rakic,et al.  Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys , 1994, Psychopharmacology.

[5]  Christer Halldin,et al.  PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor , 2005, Psychopharmacology.

[6]  H. Fukuda,et al.  D1 dopamine receptor binding in mood disorders measured by positron emission tomography , 2005, Psychopharmacology.

[7]  G. Bietti,et al.  BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[8]  D. Hoyer,et al.  5-HT1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.

[9]  L. Farde,et al.  PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride , 2004, Psychopharmacology.

[10]  H. Moore,et al.  Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia , 2003, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[11]  R. Baldessarini,et al.  Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. , 2003, European Journal of Pharmacology.

[12]  Marc Laruelle,et al.  Dopamine Depletion and In Vivo Binding of PET D1 Receptor Radioligands: Implications for Imaging Studies in Schizophrenia , 2003, Neuropsychopharmacology.

[13]  R. Mailman,et al.  Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. , 2002, The Journal of pharmacology and experimental therapeutics.

[14]  G. Sedvall,et al.  PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. , 2002, The American journal of psychiatry.

[15]  R. V. Van Heertum,et al.  Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia , 2002, The Journal of Neuroscience.

[16]  J. Hirvonen,et al.  Measurement of Cortical Dopamine D1 Receptor Binding with [11C]SCH 23390: A Test–Retest Analysis , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  W C Eckelman,et al.  Kinetic Analysis of the 5-HT2A Ligand [11C]MDL 100,907 , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  P. Goldman-Rakic,et al.  D1 receptors in prefrontal cells and circuits , 2000, Brain Research Reviews.

[19]  Christer Halldin,et al.  Measurement of Striatal and Extrastriatal Dopamine D1 Receptor Binding Potential With [11C]NNC 112 in Humans: Validation and Reproducibility , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  David R. Sibley,et al.  Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes , 1999, Neuropsychopharmacology.

[21]  F. Bymaster,et al.  Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α 1-adrenergic receptors in vitro , 1999, Schizophrenia Research.

[22]  J Sandell,et al.  Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  Roger N. Gunn,et al.  Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET , 1998, NeuroImage.

[24]  R. V. Parsey,et al.  Kinetic Derivation of Serotonin 5HT-1A Receptor Binding Potential with [11C]Carbonyl-Way 100635 and Competition Studies with Endogenous Serotonin , 1998, NeuroImage.

[25]  Roger N. Gunn,et al.  Tracer Kinetic Modelling of the 5-HT1A Receptor Ligand [carbonyl-11C]WAY-100635 , 1998, NeuroImage.

[26]  M Schulzer,et al.  Reproducibility of the distribution of carbon-11-SCH 23390, a dopamine D1 receptor tracer, in normal subjects. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  Christer Halldin,et al.  PET Studies of Binding Competition between Endogenous Dopamine and the D1 Radiotracer [11C]NNC 756 , 1998, NeuroImage.

[28]  J. Seamans,et al.  D1 Receptor Modulation of Hippocampal–Prefrontal Cortical Circuits Integrating Spatial Memory with Executive Functions in the Rat , 1998, The Journal of Neuroscience.

[29]  G Brix,et al.  Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  I Izquierdo,et al.  Involvement of hippocampal cAMP/cAMP-dependent protein kinase signaling pathways in a late memory consolidation phase of aversively motivated learning in rats. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Iyo,et al.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.

[32]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[33]  J. Lisman,et al.  D1/D5 Dopamine Receptor Activation Increases the Magnitude of Early Long-Term Potentiation at CA1 Hippocampal Synapses , 1996, The Journal of Neuroscience.

[34]  Stanley J Watson,et al.  Dopamine Receptor mRNA Expression in Human Striatum and Neocortex , 1996, Neuropsychopharmacology.

[35]  K. Bogeso,et al.  Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity. , 1995, Journal of medicinal chemistry.

[36]  P. Goldman-Rakic,et al.  Modulation of memory fields by dopamine Dl receptors in prefrontal cortex , 1995, Nature.

[37]  E. Kandel,et al.  D1/D5 receptor agonists induce a protein synthesis-dependent late potentiation in the CA1 region of the hippocampus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J O Rinne,et al.  PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  Christer Halldin,et al.  Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain , 1994, Neuropsychopharmacology.

[40]  Robert B. Innis,et al.  SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: II. Equilibrium Analysis of Constant Infusion Experiments and Correlation with in vitro Parameters , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[41]  P. Goldman-Rakic,et al.  The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. , 1994, Journal of neurophysiology.

[42]  G. Sedvall,et al.  [11C]NNC 687 and [11C]NNC 756, dopamine D-1 receptor ligands. Preparation, autoradiography and PET investigation in monkey. , 1993, Nuclear medicine and biology.

[43]  R. Mailman,et al.  Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents. , 1993, European journal of pharmacology.

[44]  J. Mazziotta,et al.  MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.

[45]  J. Miller,et al.  In vitro and in vivo pharmacological characterization of N6-cyclopentyl-9-methyladenine (N-0840): a selective, orally active A1 adenosine receptor antagonist. , 1993, The Journal of pharmacology and experimental therapeutics.

[46]  C. Braestrup,et al.  NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. , 1992, European journal of pharmacology.

[47]  B. Roth,et al.  Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. , 1992, The Journal of pharmacology and experimental therapeutics.

[48]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[49]  J. Kleinman,et al.  Characterization of [125I]SCH 23982 binding in human brain: Comparison with [3H]SCH 23390 , 1991, Neuroscience Letters.

[50]  Susan R. George,et al.  Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 , 1991, Nature.

[51]  V. Simonneaux,et al.  Characterization of D1 dopamine receptors in the bovine pineal gland with [3H]SCH 23390. , 1990, The Journal of pharmacology and experimental therapeutics.

[52]  D. Geschwind,et al.  Distribution of major neurotransmitter receptors in the motor and somatosensory cortex of the rhesus monkey , 1989, Neuroscience.

[53]  R. Mcquade,et al.  Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. , 1988, The Journal of pharmacology and experimental therapeutics.

[54]  Frank Roels,et al.  Autoradiographic localization of D1 and D2 dopamine receptors in the human brain , 1988, Neuroscience Letters.

[55]  D. Riche,et al.  Anatomical atlas of the baboon's brain in the orbito-meatal plane used in experimental positron emission tomography , 1988, Brain Research Bulletin.

[56]  P. H. Andersen.  Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. , 1988, European journal of pharmacology.

[57]  D. Weinberger.  Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[58]  S. Stone-Elander,et al.  Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. , 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[59]  P. H. Andersen,et al.  A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum. , 1985, Life sciences.

[60]  A. Barnett,et al.  Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. , 1984, Life sciences.

[61]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[62]  T D Cradduck,et al.  National electrical manufacturers association , 1983, Journal of the A.I.E.E..